# Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT02546986** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 100 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** CC-486
- **DRUG:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02546986
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-09
- **Primary completion:** 2017-04-13
- **Final completion:** 2025-07-07
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02546986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02546986, "Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02546986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*